These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17315755)

  • 41. Placebo effect and dopamine release.
    de la Fuente-Fernández R; Lidstone S; Stoessl AJ
    J Neural Transm Suppl; 2006; (70):415-8. PubMed ID: 17017561
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New insights into the placebo and nocebo responses.
    Enck P; Benedetti F; Schedlowski M
    Neuron; 2008 Jul; 59(2):195-206. PubMed ID: 18667148
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The biochemical bases of the placebo effect.
    de la Fuente-Fernández R; Stoessl AJ
    Sci Eng Ethics; 2004 Jan; 10(1):143-50. PubMed ID: 14986780
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss.
    Aarts E; Helmich RC; Janssen MJ; Oyen WJ; Bloem BR; Cools R
    Neuroimage; 2012 Feb; 59(4):3339-46. PubMed ID: 22166793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The subthalamic nucleus and the placebo effect in Parkinson's disease.
    Frisaldi E; Zamfira DA; Benedetti F
    Handb Clin Neurol; 2021; 180():433-444. PubMed ID: 34225946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries.
    Fricchione G; Stefano GB
    Med Sci Monit; 2005 May; 11(5):MS54-65. PubMed ID: 15874901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies.
    Diederich NJ; Goetz CG
    Neurology; 2008 Aug; 71(9):677-84. PubMed ID: 18725593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Facilitative effects of bi-hemispheric tDCS in cognitive deficits of Parkinson disease patients.
    Leite J; Gonçalves OF; Carvalho S
    Med Hypotheses; 2014 Feb; 82(2):138-40. PubMed ID: 24332532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine, reward, and frontostriatal circuitry in impulse control disorders in Parkinson's disease: insights from functional imaging.
    Ray N; Strafella AP
    Clin EEG Neurosci; 2010 Apr; 41(2):87-93. PubMed ID: 20521491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.
    Murray D; Stoessl AJ
    Pharmacol Ther; 2013 Dec; 140(3):306-18. PubMed ID: 23880289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study.
    Sacheli MA; Murray DK; Vafai N; Cherkasova MV; Dinelle K; Shahinfard E; Neilson N; McKenzie J; Schulzer M; Appel-Cresswell S; McKeown MJ; Sossi V; Jon Stoessl A
    Mov Disord; 2018 Dec; 33(12):1945-1950. PubMed ID: 30376184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Individual differences in reward responding explain placebo-induced expectations and effects.
    Scott DJ; Stohler CS; Egnatuk CM; Wang H; Koeppe RA; Zubieta JK
    Neuron; 2007 Jul; 55(2):325-36. PubMed ID: 17640532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.
    Pal G; Ouyang B; Verhagen L; Serrano G; Shill HA; Adler CH; Beach TG; Kordower JH;
    Mov Disord; 2018 Apr; 33(4):652-654. PubMed ID: 29380902
    [No Abstract]   [Full Text] [Related]  

  • 54. Understanding the placebo effect: contributions from neuroimaging.
    Lidstone SC; Stoessl AJ
    Mol Imaging Biol; 2007; 9(4):176-85. PubMed ID: 17334853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The sweetest pill to swallow: how patient neurobiology can be harnessed to maximise placebo effects.
    Jubb J; Bensing JM
    Neurosci Biobehav Rev; 2013 Dec; 37(10 Pt 2):2709-20. PubMed ID: 24055773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dopamine signals and physiological origin of cognitive dysfunction in Parkinson's disease.
    Matsumoto M
    Mov Disord; 2015 Apr; 30(4):472-83. PubMed ID: 25773863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Placebo and nocebo effects: a complex interplay between psychological factors and neurochemical networks.
    Frisaldi E; Piedimonte A; Benedetti F
    Am J Clin Hypn; 2015 Jan; 57(3):267-84. PubMed ID: 25928679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of the placebo response.
    Benedetti F; Amanzio M
    Pulm Pharmacol Ther; 2013 Oct; 26(5):520-3. PubMed ID: 23370213
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mind matters: placebo enhances reward learning in Parkinson's disease.
    Schmidt L; Braun EK; Wager TD; Shohamy D
    Nat Neurosci; 2014 Dec; 17(12):1793-7. PubMed ID: 25326691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding the placebo effect. Part 2: underlying psychological & neurobiological processes.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Jun; 46(6):15-8. PubMed ID: 18595454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.